PMID- 27159403
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20220408
IS  - 1525-6006 (Electronic)
IS  - 1064-1963 (Linking)
VI  - 38
IP  - 4
DP  - 2016
TI  - The association between oxidative stress, activator protein-1, inflammatory, 
      total antioxidant status and artery stiffness and the efficacy of olmesartan in 
      elderly patients with mild-to-moderate essential hypertension.
PG  - 365-9
LID - 10.3109/10641963.2015.1131285 [doi]
AB  - This study investigated the change of oxidative stress, activator protein-1 
      (AP-1), inflammatory, total antioxidant status (TAS) and artery stiffness, and 
      explored the relationship between these characteristics and the efficacy of 
      olmesartan intervention in elderly patients with mild-to-moderate essential 
      hypertension (EH). In total, 386 elderly patients with EH and 353 normotensive 
      controls were recruited. All study subjects had oxidative stress markers, AP-1, 
      inflammatory factors, TAS and brancial-ankle artery pulse wave velocity (ba-PWV) 
      measured. In total, 193 elderly patients with EH were randomized to olmesartan 
      and were matched with 193 normotensive controls to observe the change of index 
      above mentioned before and after the treatment. Compared with the controls, 
      superoxide dismutase (SOD) and TAS were significantly reduced in patients with 
      EH, and malondialdehyde (MDA), AP-1, high-sensitivity C-reactive protein 
      (Hs-CRP), Monocyte Chemoattractant Protein-1 (MCP-1), heart rate， endothelin-1 
      (ET-1), TAS and ba-PWV were significantly increased (P < 0.01 for all). Pearson's 
      correlation analysis showed that SOD and TAS were negatively related to AP-1 (P < 
      0.05 for all), and that blood pressure (BP), age, MDA, Hs-CRP, MCP-1, ET-1 were 
      positively related to AP-1 (P < 0.01 for all). Multivariate linear regression 
      analysis showed that BP, SOD, MDA, AP-1, Hs-CRP, MCP-1, ET-1, TAS, heart rate and 
      age were independent risk factors for ba-PWV. After treatment with olmesartan, 
      SOD and TAS were increased, while BP, heart rate, AP-1 and inflammatory factors 
      were reduced with significant improvement in ba-PWV (P < 0.05 for all). More 
      increase of arterial stiffness was reported in elderly hypertensive patients with 
      greater oxidative stress, inflammatory, AP-1, heart rate, and lower TAS. Higher 
      oxidative stress, AP-1 and inflammatory may predict higher arterial stiffness. 
      Olmesartan may increase TAS, yet inhibit oxidative stress, AP-1, inflammatory, 
      and heart rate with improved artery stiffness in elderly hypertensive patients.
FAU - Liu, Qunwei
AU  - Liu Q
AD  - a Department of Cardiology , Civil Aviation General Hospital Affiliated to 
      BeiJing University , Beijing , PR China.
FAU - Han, Limin
AU  - Han L
AD  - a Department of Cardiology , Civil Aviation General Hospital Affiliated to 
      BeiJing University , Beijing , PR China.
FAU - Du, Qiufan
AU  - Du Q
AD  - a Department of Cardiology , Civil Aviation General Hospital Affiliated to 
      BeiJing University , Beijing , PR China.
FAU - Zhang, Ming
AU  - Zhang M
AD  - b Department of Cardiology , An Zhen Hospital Affiliated to Capital Medical 
      University , Beijing , PR China.
FAU - Zhou, Shenghua
AU  - Zhou S
AD  - c Department of Cardiology , Xiangya Second Hospital of Central South University 
      , Changsha , PR China.
FAU - Shen, Xiangqian
AU  - Shen X
AD  - c Department of Cardiology , Xiangya Second Hospital of Central South University 
      , Changsha , PR China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160509
PL  - England
TA  - Clin Exp Hypertens
JT  - Clinical and experimental hypertension (New York, N.Y. : 1993)
JID - 9305929
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Imidazoles)
RN  - 0 (Tetrazoles)
RN  - 0 (Transcription Factor AP-1)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 8W1IQP3U10 (olmesartan)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
SB  - IM
MH  - Aged
MH  - Antihypertensive Agents/administration & dosage/adverse effects
MH  - Biomarkers/blood
MH  - *Blood Pressure/drug effects/physiology
MH  - C-Reactive Protein/metabolism
MH  - Drug Monitoring/methods
MH  - Essential Hypertension
MH  - Female
MH  - Humans
MH  - *Hypertension/diagnosis/drug therapy/metabolism/physiopathology
MH  - *Imidazoles/administration & dosage/adverse effects
MH  - Male
MH  - Malondialdehyde/blood
MH  - Oxidative Stress/drug effects/physiology
MH  - Pulse Wave Analysis/methods
MH  - Risk Factors
MH  - Superoxide Dismutase/blood
MH  - *Tetrazoles/administration & dosage/adverse effects
MH  - Transcription Factor AP-1/blood
MH  - Treatment Outcome
MH  - *Vascular Stiffness/drug effects/physiology
OTO - NOTNLM
OT  - Activator protein-1
OT  - artery stiffness
OT  - elderly patients
OT  - inflammatory
OT  - mild-to-moderate essential hypertension
OT  - olmesartan
OT  - oxidative stress
OT  - total antioxidant status
EDAT- 2016/05/10 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/05/10 06:00
PHST- 2016/05/10 06:00 [entrez]
PHST- 2016/05/10 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.3109/10641963.2015.1131285 [doi]
PST - ppublish
SO  - Clin Exp Hypertens. 2016;38(4):365-9. doi: 10.3109/10641963.2015.1131285. Epub 
      2016 May 9.